Top Markets
Coin of the day
Virpax Pharmaceuticals, Inc. Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc.

VRPX
株式のランク #42776
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical... Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$124.00
変化(1日)
0.00%
変化(1年)
-99.09%
US
取引 Virpax Pharmaceuticals, Inc. (VRPX)

カテゴリー

Virpax Pharmaceuticals, Inc.(VRPX)の株式分割履歴
Virpax Pharmaceuticals, Inc.株(シンボル:VRPX)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 12, 2026に行われました。
Aug 12, 2026より前に購入されたVRPX株は、現在0VRPX株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
CH
0 -
BE
0 -
KR